Anticorps Recombinant de lapin anti-IL-4

IL-4 Recombinant Antibody for FC (Intra)

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC (Intra)

Conjugaison

Non conjugué

CloneNo.

240794E11

N° de cat : 98138-1-RR

Synonymes

IL4, interleukin 4, IL 4, BSF-1, B-cell stimulatory factor 1



Applications testées

Résultats positifs en FC (Intra)PMA, Ionomycin and Brefeldin A treated human PBMCs,

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98138-1-RR cible IL-4 dans les applications de FC (Intra) et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Protéine recombinante
Nom complet interleukin 4
Masse moléculaire calculée 153 aa, 17 kDa
Numéro d’acquisition GenBankBC070123
Symbole du gène IL-4
Identification du gène (NCBI) 3565
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

IL-4 is a cytokine produced by CD4+ T cells in response to helminthes and other extracellular parasites. It promotes the proliferation and differentiation of antigen presenting cells. IL-4 also plays a pivotal role in antibody isotype switching and stimulates the production of IgE. This cytokine has been applied in the treatment of autoimmune disorder like multiple myeloma, cancer, psoriasis, and arthritis. IL-4 has also been extensively applied to inhibit detrimental effect of Th1. It may promote the growth of epithelial tumors by mediating increased proliferation and survival.

Protocole

Product Specific Protocols
FC protocol for IL-4 antibody 98138-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}